ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer

Drug Shows CNS Activity In Early Trial

 
• By Mandy Jackson
  
Lungs paper decorative model on light blue background
EGFR PACC mutations are more common in NSCLC than exon 20 insertion mutations • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D